Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Faisal Mehmed, MD
Vice President
Clinical Development & Medical Affairs
Novartis Pharmaceuticals Oncology
East Hanover, NJ
Vice President
Clinical Development & Medical Affairs
Novartis Pharmaceuticals Oncology
East Hanover, NJ
Authored Items
Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges
Alan L. Shields, PhD
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Yanni Hao, PhD
,
Meaghan Krohe, PhD
,
Andrew Yaworsky
,
Iyar Mazar, MA
,
Catherine Foley, MPH, MA
,
Faisal Mehmed, MD
,
Denise Globe, PhD
June 2016 Vol 9, No 4
in
Practice Management
Last modified: June 24, 2016